title: Comparison of calcium and silicate cement and mineral trioxide aggregate biologic effects and bone markers expression in MG63 cells.
abstract: Bone cell (MG63) biocompatibility and bone marker expression were compared after calcium and silicate base cement (CS) and mineral trioxide aggregate (MTA) treatment. X-ray diffraction was used to identify material surface structure, and tetrazolium bromide colorimetric assay was used to evaluate the cell viability. The relative mitogen activation protein kinase expression was compared with Western blot, and bone marker expression was evaluated with reverse transcriptase polymerization chain reaction. The results showed that CS and MTA are similar chemical structures and biocompatible with MG63 cells. CS and MTA cements showed good MG63 cell proliferation by high phosphor extracellular signal-regulated kinase expression levels. CS and MTA cements showed the evident type I collagen, osteocalcin, alkaline phosphatase, bone sialoprotein, and osteopontin expression. Both MTA and CS cements are biocompatible and appear to have osetoconduction effects on bone cells.
authors.affiliation: Institute of Oral Biology and Material Science, Chung Shan Medical University, Taichung, Taiwan.
authors.forename: Chih-Lin
authors.initials: CL
authors.lastname: Chen
authors.forename: Tsui-Hsien
authors.initials: TH
authors.lastname: Huang
authors.forename: Shinn-Jyh
authors.initials: SJ
authors.lastname: Ding
authors.forename: Ming-You
authors.initials: MY
authors.lastname: Shie
authors.forename: Chia-Tze
authors.initials: CT
authors.lastname: Kao
mesh_terms: D000469:Alkaline Phosphatase / Q000032:analysis; D017607:Aluminum Compounds / Q000494:pharmacology*; D001672:Biocompatible Materials / Q000494:pharmacology*; D015415:Biomarkers / Q000032:analysis; D015153:Blotting, Western; D017610:Calcium Compounds / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002470:Cell Survival; D024042:Collagen Type I / Q000032:analysis; D003124:Colorimetry; D004396:Coloring Agents; D004338:Drug Combinations; D048049:Extracellular Signal-Regulated MAP Kinases / Q000032:analysis; D006801:Humans; D058574:Integrin-Binding Sialoprotein; D008422:Materials Testing; D020928:Mitogen-Activated Protein Kinases / Q000032:analysis; D010006:Osteoblasts / Q000187:drug effects*; D053495:Osteopontin / Q000032:analysis; D010087:Oxides / Q000494:pharmacology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012387:Root Canal Filling Materials / Q000494:pharmacology*; D012795:Sialoglycoproteins / Q000032:analysis; D017640:Silicates / Q000494:pharmacology*; D013778:Tetrazolium Salts; D013844:Thiazoles; D013997:Time Factors; D014961:X-Ray Diffraction
chemical_list: D017607:Aluminum Compounds; D001672:Biocompatible Materials; D015415:Biomarkers; D017610:Calcium Compounds; D024042:Collagen Type I; D004396:Coloring Agents; D004338:Drug Combinations; C546871:IBSP protein, human; D058574:Integrin-Binding Sialoprotein; D010087:Oxides; D012387:Root Canal Filling Materials; D012795:Sialoglycoproteins; D017640:Silicates; D013778:Tetrazolium Salts; D013844:Thiazoles; C086631:mineral trioxide aggregate; D053495:Osteopontin; D048049:Extracellular Signal-Regulated MAP Kinases; D020928:Mitogen-Activated Protein Kinases; D000469:Alkaline Phosphatase; C022616:thiazolyl blue; C031293:calcium silicate